The NHS has launched a revolutionary blood test that detects cancer through circulating tumor DNA, enabling faster, more personalized treatments for lung and breast cancer patients: https://t.co/MfN2KXTFna

At Poscidon, we're pushing personalized medicine even further. Our weCURA platform uses gene expression data and AI to predict individual responses to cancer therapies, focusing on aggressive cancers like pancreatic and brain tumors.

While the NHS is transforming diagnostics, Poscidon is revolutionizing treatment selection.

Together, we're moving beyond one-size-fits-all medicine to truly individualized care.

Learn more about weCURA below 👇